Company

Therakos, Inc.

Therakos makes the CELLEX Photopheresis System and UVADEX for treating Cutaneous T-Cell Lymphoma.

About

Therakos, Inc. develops medical solutions for Cutaneous T-Cell Lymphoma (CTCL) using extracorporeal photopheresis. Its THERAKOS CELLEX Photopheresis System uses UVA irradiation with the photoactive drug UVADEX (methoxsalen), and is sold to healthcare institutions. CVC and individual investors acquired the company from Mallinckrodt, Inc. for USD 925 million on August 5, 2024, and the company has completed three deals. Its headquarters is listed in Staines-upon-Thames, UK.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in